Anika Therapeutics Inc

ANIK is in a Stage 3 distribution phase, granting bearish medium-term permission. Short-term price is rejecting around the 9/21 EMAs and 50-day SMA, reflecting diminishing demand and structure failure. The preferred execution is selling into rallies near these resistance zones, aligning with the dominant downtrend while respecting potential short-term oversold bounces.

• ↑Q1 2026 commercial channel revenue grew 12% YoY to $12.6M.
• ↑Gross margins expanded to 64% from 56% via productivity gains.
• ↓Q1 OEM channel revenue declined 23% YoY from pricing pressure.